Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the drug market for mild cognitive impairment (MCI) will be driven primarily by rising prevalence as the population ages and by increases in the drug-treated patient population over the next eight years. In 2004, there were a reported 29 million cases of mild cognitive impairment in the major markets.
"Although few diagnosed patients are currently drug-treated, the treatment rate will grow significantly as diagnostic markers enter the market and the first drugs targeting the pathophysiology of amnestic MCI launch in the United States and in Europe," says Andrea Witt, Ph.D., a Decision Resources analyst.
The new report, entitled Mild Cognitive Impairment -- An Indication on the Verge of Maturity, also finds that opportunity abounds for an emerging therapy in the MCI market and that the efficacy bar for an emerging therapy is low. Because of the heterogeneity of the MCI population and because the end points necessary to demonstrate efficacy are still being established, few drugs in development have convincingly shown an ability to cause a delay in the conversion of MCI to dementia. For instance, the acetylcholinesterase inhibitors (AChEls) currently used as first-line therapy in the treatment of MCI have shown little efficacy in preventing MCI patients from converting to dementia in recent Phase III trials.
About Mild Cognitive Impairment -- An Indication on the Verge of Maturity from Decision Resources
Mild Cognitive Impairment -- An Indication on the Verge of Maturity covers the current state of the MCI drug market. The report includes:
* Analysis of the MCI market focused on the diagnosed/drug-treated populations, patient/market share projections, cost per day, and compliance expectations. * Market projections driven by the projected attributes for a novel agent. * Assessment of the MCI market driven by qualitative interviews with KOLs and survey results from high prescribing physicians defining their target product profile.
The report can be purchased by contacting Decision Resources. Members of the media may request a complimentary copy.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/